Biology Reference
In-Depth Information
[52] Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ, et al. Pharmacokinetics
and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-
matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow
Transplant 2003;9:460-71.
[53] Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, et al.
T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-30.
[54] Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance main-
tained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of
a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol
1995;155:1151-64.
[55] Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+
natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immu-
nol Rev 2006;212:8-27.
[56] Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)
CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood
2002;99:3493-9.
[57] Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+
regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-
host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
[58] Buitenhuis M, Verhagen LP, van Deutekom HW, Castor A, Verploegen S, Koenderman L,
et al. Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during
myelopoiesis. Blood 2008;111:112-21.
[59] Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of
Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004;104:2187-93.
[60] Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Ab-
sence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoim-
mune-mediated pathology in chronic graft-versus-host disease. Blood 2007;110:
3804-13.
[61] Zorn E, Mohseni M, Kim H, Porcheray F, Lynch A, Bellucci R, et al. Combined CD4+
donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory
T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant 2009;15:382-8.
[62] Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3
expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mecha-
nism and induces the expansion of these cells in vivo. Blood 2006;108:1571-9.
[63] Tsoi MS, Storb R, Jones E, Weiden PL, Shulman H, Witherspoon R, et al. Deposition of
IgM and complement at the dermoepidermal junction in acute and chronic cutaneous
graft-vs-host disease in man. J Immunol 1978;120:1485-92.
[64] Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, Mestroni R, et al. The development of
autoantibodies after allogeneic stem cell transplantation is related with chronic graft-
vs-host disease and immune recovery. Exp Hematol 2006;34:389-96.
[65] Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y
minor histocompatibility antigens correlate with chronic graft-versus-host disease and
disease remission. Blood 2005;105:2973-8.
[66] Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, et al. Antibody re-
sponse to DBY minor histocompatibility antigen is induced after allogeneic stem cell
transplantation and in healthy female donors. Blood 2004;103:353-9.
[67] Rolink AG, Radaszkiewicz T, Melchers F. Monoclonal autoantibodies specific for kidney
proximal tubular brush border from mice with experimentally induced chronic graft-
versus-host disease. Scand J Immunol 1988;28:29-41.
[68] Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory
autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host
disease. Blood 2007;110:237-41.
[69] Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment
of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.
Biol Blood Marrow Transplant 2003;9:505-11.
[70] Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG,
Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-
refractory chronic graft-versus-host disease. Blood 2004;104:2603-6.
[71] Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-
refractory chronic graft-versus-host disease. Blood 2006;108:756-62.
[72] Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy
of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a
systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15:1005-13.
[73] Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage
therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909-11.
321
Search WWH ::
Custom Search